Dubai Chamber: UAE medical tourism hit AED 12.1bn as 154 hospitals competed

Dubai Chamber of Commerce and Industry put UAE medical tourism sales at AED 12.1 billion in 2018, up 5.5%, giving hospital CEOs and CFOs a benchmark for foreign patient revenue.

The number matters most to executives at private hospitals, where overseas patients can affect pricing, capacity and collections. It shows medical tourism was already a national revenue pool before the post-pandemic travel rebound, and it gives operators a baseline for planning under Dubai Health Authority (DHA), Department of Health Abu Dhabi (DOH) and Ministry of Health and Prevention (MOHAP) licensing regimes.

What the 2018 numbers show

The WAM report carried by Zawya said the Dubai Chamber analysis used data from Euromonitor International and Fitch Solutions. UAE health expenditure reached an estimated AED 50.3 billion in 2018, up 5.4% from 2017.

• AED 12.1 billion: UAE medical tourism sales in 2018.
• 5.5%: year-on-year growth in medical tourism sales.
• 154 hospitals: UAE hospital count in 2018, up from 107 in 2013.
• 49.1 million: patient visits recorded by UAE hospitals in 2018.

Those numbers make medical tourism a board-level revenue question. A hospital with overseas patient flow needs pricing governance, multilingual conversion funnels, payer documentation and surgeon availability. CFOs should track foreign patient revenue as a separate line, with its own acquisition cost, approval cycle and cash collection risk.

DHA and DOH built patient channels

DHA created the Dubai Health Experience portal to help Dubai providers sell treatment packages online, including appointments, travel support and procedure information. DOH and the Department of Culture and Tourism Abu Dhabi launched an Abu Dhabi medical tourism e-portal to present facilities and services to visitors in the emirate.

For CIOs, the issue is integration across booking, patient identity checks, secure file transfer, pre-travel teleconsultation and post-discharge follow-up. For COOs, the risk sits in handoffs between travel, registration, consent, surgery and billing, where delays can cut the margin on an international case.

“Dubai has emerged as one of the world’s leading healthcare destinations in recent years.” — Dr. Marwan Al Mulla, Chief Executive Officer, Health Regulation Sector, DHA

The DHA Health Investment Guide 2024 shows how Dubai’s operating base changed after 2018. Dubai healthcare expenses reached about AED 21.4 billion in 2022, while 98% of Dubai’s population had medical insurance coverage. The guide also reported that 73% of outpatient visits and 83% of inpatient visits in 2022 went to private facilities.

The operator takeaway

Dubai Chamber projected medical tourism sales could reach AED 19.5 billion by 2023. That forecast came before Covid-19 disrupted travel, so operators should avoid treating it as a clean growth line. The useful lesson is market structure: private providers were already being pulled toward high-margin specialties such as orthopaedics, dermatology, dentistry, fertility and elective surgery.

MOHAP matters for Northern Emirates operators seeking spillover demand from Dubai and Abu Dhabi. DHA matters where the patient journey is sold through Dubai channels. DOH matters where Abu Dhabi facilities combine treatment with destination marketing. Each regulator controls licensing, facility standards and clinical scope in its jurisdiction.

The next question is yield. CEOs should ask whether international patients produce higher net revenue than insured residents after marketing, translation, travel coordination and follow-up costs. CFOs should compare payer mix by specialty. COOs should audit turnaround time for enquiry-to-consultation and consultation-to-procedure. The number to remember is AED 12.1 billion: a historical baseline for testing which providers can convert medical tourism demand into controlled margin.